{"groups":[{"description":"Bevacizumab infusions were administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) was administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.","id":"FG000","title":"Bevacizumab + IFN-Alfa-2A"},{"description":"Placebo matched with Bevacizumab infusions were administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"FG001","title":"Placebo + IFN-Alfa-2A"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"224"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"327"},{"groupId":"FG001","numSubjects":"322"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"325"},{"groupId":"FG001","numSubjects":"316"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"93"},{"groupId":"FG001","numSubjects":"84"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"234"},{"groupId":"FG001","numSubjects":"238"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 821 participants were screened for this study, and 649 of these were randomized to receive double-blind treatment."}